References
- Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971–984.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
- Kudchadkar RR, Lowe MC, Khan MK, et al. Metastatic melanoma. CA Cancer J Clin. 2020;70(2):78–85.
- Sun J, Carr MJ, Khushalani NI. Principles of targeted therapy for melanoma. Surg Clin North Am. 2020;100(1):175–188.
- Albittar AA, Alhalabi O, Glitza Oliva IC. Immunotherapy for melanoma. Adv Exp Med Biol. 2020;1244:51–68.
- Cho H. Protein tyrosine phosphatase 1B (PTP1B) and obesity. Vitam Horm. 2013;91:405–424.
- Hussain H, Green IR, Abbas G, et al. Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018). Expert Opin Ther Pat. 2019;29(9):689–702.
- Dodd GT, Xirouchaki CE, Eramo M, et al. Intranasal targeting of hypothalamic PTP1B and TCPTP reinstates leptin and insulin sensitivity and promotes weight loss in obesity. Cell Rep. 2019;28(11):2905–2922.e2905.
- Labbé DP, Uetani N, Vinette V, et al. PTP1B deficiency enables the ability of a high-fat diet to drive the invasive character of PTEN-deficient prostate cancers. Cancer Res. 2016;76(11):3130–3135.
- Yu M, Liu Z, Liu Y, et al. PTP 1B markedly promotes breast cancer progression and is regulated by miR-193a-3p. FEBS J. 2019;286(6):1136–1153.
- Wang W, Cao Y, Zhou X, et al. PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism. Biochem Biophys Res Commun. 2018;503(2):903–909.
- Liu H, Wu Y, Zhu S, et al. PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer. Cancer Lett. 2015;359(2):218–225.
- Zhu S, Bjorge JD, Fujita DJ. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res. 2007;67(21):10129–10137.
- Wang N, She J, Liu W, et al. Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients. Cell Cycle. 2015;14(5):732–743.
- Xu Q, Wu N, Li X, et al. Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway. Cell Death Dis. 2019;10(12):874.
- Arias-Romero LE, Saha S, Villamar-Cruz O, et al. Activation of Src by protein tyrosine phosphatase 1B is required for ErbB2 transformation of human breast epithelial cells. Cancer Res. 2009;69(11):4582–4588.
- Zahn M, Marienfeld R, Melzner I, et al. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells. Blood. 2017;129(11):1480–1490.
- Lu X, Malumbres R, Shields B, et al. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood. 2008;112(10):4098–4108.
- Roskoski R Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 2015;94:9–25.
- Patel A, Sabbineni H, Clarke A, et al. Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sci. 2016;157:52–61.
- Amata I, Maffei M, Pons M. Phosphorylation of unique domains of Src family kinases. Front Genet. 2014;5:181.
- Zhang H, Forman HJ. TGFβ1 rapidly activates Src through a non-canonical redox mechanism. Free Radic Biol Med. 2014;75(Suppl 1):S4.
- Wang J, Yu L, Zheng X. PTPα-mediated Src activation by EGF in human breast cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013;45(4):320–329.
- Wang Q, Qian L, Tao M, et al. Knockdown of DEAD-box RNA helicase 52 (DDX52) suppresses the proliferation of melanoma cells in vitro and of nude mouse xenografts by targeting c-Myc. Bioengineered. 2021;12(1):3539–3549.
- Wang Q, Peng R, Wang B, et al. Transcription factor KLF13 inhibits AKT activation and suppresses the growth of prostate carcinoma cells. Cancer Biomarkers. 2018;22(3):533–541.
- Ying J, Wang Q, Lu L, et al. Fermitin family homolog 2 (Kindlin-2) affects vascularization during the wound healing process by regulating the Wnt/β-catenin signaling pathway in vascular endothelial cells. Bioengineered. 2021;12(1):4654–4665.
- Pan BQ, Xie ZH, Hao JJ, et al. PTP1B up-regulates EGFR expression by dephosphorylating MYH9 at Y1408 to promote cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2020;522(1):53–60.
- Teng HW, Hung MH, Chen LJ, et al. Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma. Sci Rep. 2017;7(1):45612.
- Egan C, Pang A, Durda D, et al. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene. 1999;18(5):1227–1237.
- Zhu S, Bjorge JD, Fujita DJ. SRC is dephosphorylated at tyrosine 530 in human colon carcinomas. Chin J Cancer Res. 2011;23(3):229–231.
- Pallen CJ. Protein tyrosine phosphatase α (PTPα): a Src family kinase activator and mediator of multiple biological effects. Curr Top Med Chem. 2003;3(7):821–835.
- Cardone L, Carlucci A, Affaitati A, et al. Mitochondrial AKAP121 binds and targets protein tyrosine phosphatase D1, a novel positive regulator of src signaling. Mol Cell Biol. 2004;24(11):4613–4626.
- Zhang Z, Lin SY, Neel BG, et al. Phosphorylated alpha-actinin and protein-tyrosine phosphatase 1B coregulate the disassembly of the focal adhesion kinase x Src complex and promote cell migration. J Biol Chem. 2006;281(3):1746–1754.
- Brandt DT, Goerke A, Heuer M, et al. Protein kinase C delta induces Src kinase activity via activation of the protein tyrosine phosphatase PTP alpha. J Biol Chem. 2003;278(36):34073–34078.
- Fang KS, Sabe H, Saito H, et al. Comparative study of three protein-tyrosine phosphatases. Chicken protein-tyrosine phosphatase lambda dephosphorylates c-Src tyrosine 527. J Biol Chem. 1994;269(31):20194–20200.
- Somani AK, Bignon JS, Mills GB, et al. Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase. J Biol Chem. 1997;272(34):21113–21119.